ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,701 companies indexed · Last updated: today
DirectoryIndustryMedical Technology IndustryBernBLEEDnFIRE Therapeutics AG
BLEEDnFIRE Therapeutics AG Logo
Verified· 2 sourcesTrust Score
Summary

About the company

BLEEDnFIRE Therapeutics AG is a biotechnology company developing RNA-based therapies for bleeding disorders. Its lead program, BnF-001, is a siRNA platform designed to modulate Protein S and restore hemostatic balance.

AI-generated
Offering

Products & services

Industry:Medical Technology IndustryPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
No score yet

BLEEDnFIRE Therapeutics AG

✓ Offered3
RNA Therapies for Bleeding Disorders
RNA-based therapies for hemophilia and rare bleeding disorders, with hemostatic rebalancing, a factor-independent mechanism, and development as prophylactic subcutaneous treatment.
Protein S-targeting siRNA Therapy
Liver-targeted, GalNAc-conjugated siRNA to reduce protein S in a controlled way, increase thrombin generation, and rebalance hemostasis in bleeding disorders.
Development of BnF-001
BnF-001 as lead asset: GalNAc-conjugated, subcutaneously administered siRNA for targeted PROS1 silencing, with potential for long-acting prophylaxis and broad applicability.
Trust & reputation

ranQ Trust Score of BLEEDnFIRE Therapeutics AG

Trust Score

No score yet

x

A published score requires a data basis of at least 50% and data from at least two criteria groups other than identity. Missing evidence: Review quality, Review volume, Review recency, Website authority, Media authority

Data basis 50% · As of October 2026

BLEEDnFIRE Therapeutics AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
BLEEDnFIRE Therapeutics AG scores 53.4 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.25.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
BLEEDnFIRE Therapeutics AG scores 83.3 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).83.322%
BLEEDnFIRE Therapeutics AG has no value in the Visibility area of the ranQ Trust Score because no data is available. The area carries 8% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Website authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%

The data basis is 50%, below the threshold at which ranQ publishes a score. Evidence is missing for: Review quality, Review volume, Review recency, Website authority, Media authority. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once BLEEDnFIRE Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

BLEEDnFIRE Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank BLEEDnFIRE Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of BLEEDnFIRE Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Weyermannsstrasse 36
3008 Bern

At a glance

Legal form
Corporation
UID
CHE-171.480.424
Founded
2025 · 1 year
Last commercial register change
November 25, 2025
Employees
1 to 10
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    SA
    Synbora AG
    Bern
    BO
    Balsiger Orthopädie-Schuhtechnik
    Bern
    IB
    International Biomedical AG
    Uetendorf
    ES
    ewimed Switzerland AG
    Bern
    KZ
    Kaech Zahntechnik AG
    Thun
    TG
    TeutschIng GmbH
    Biel/Bienne
    MT
    MTT Technologies GmbH
    Oberwangen B. Bern
    LG
    Limesone GmbH
    Langenthal